Cadence discovery: study protocol for a dose-finding and mechanism of action clinical trial of sodium benzoate in people with treatment-refractory schizophrenia
Abstract
Background: Schizophrenia is a persistent psychotic disorder often accompanied by severe disability and premature mortality. New pharmacological treatments are urgently needed. Sodium benzoate, a common food preservative holds potential to be an effective, accessible treatment for schizophrenia, though the optimal dosing and mechanism of action of the compound requires further investigation.
| Authors | Baker, Andrea; Clarke, Lachlan; Donovan, Peter; P. J. Ungerer, Jacobus; Hartel, Gunter; Bruxner, George; Cocchi, Luca; Gordon, Anne; Moudgil, Vikas; Robinson, Gail; Roy, Digant; Sohal, Ravinder; Whittle, Emma; Scott, James G. |
|---|---|
| Journal | Trials |
| Pages | 918 |
| Volume | 22 |
| Date | 1/01/2021 |
| Grant ID | |
| Funding Body | |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1186/s13063-021-05890-6 |